NCT06671444View on ClinicalTrials.gov

Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 3, 2024

Primary Completion Date

November 10, 2024

Study Completion Date

December 25, 2024

Conditions

InsomniaRenal Impairment

Interventions

DRUG

YZJ-1139

Single oral dose, 20 mg tablet

Trial Locations (3)

Unknown

Zhongda Hospital Southeast University, Nanjing

The First Affiliated Hospital of Bengbu Medical University, Bengbu

The First Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors

lead

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT06671444 - Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment | Biotech Hunter | Biotech Hunter